Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), That Have Progressed on Prior Treatment.
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), That Have Progressed on Prior Treatment.
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), That Have Progressed on Prior Treatment.
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), That Have Progressed on Prior Treatment.
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), That Have Progressed on Prior Treatment.
Status: Enrolling
Updated:  12/31/1969
OHSU Knight Cancer Institute
mi
from
Portland, OR
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), That Have Progressed on Prior Treatment.
Status: Enrolling
Updated: 12/31/1969
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), That Have Progressed on Prior Treatment.
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), That Have Progressed on Prior Treatment.
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), That Have Progressed on Prior Treatment.
Status: Enrolling
Updated:  12/31/1969
University of TX - MD Anderson Cancer Center
mi
from
Houston, TX
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), That Have Progressed on Prior Treatment.
Status: Enrolling
Updated: 12/31/1969
University of TX - MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
A Phase Ib/II Clinical Study of BBI608 in Combination With Temozolomide for Adult Patients With Recurrent or Progressed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Laura And Isaac Perlmutter Cancer Center
mi
from
New York, NY
A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
A Phase Ib/II Clinical Study of BBI608 in Combination With Temozolomide for Adult Patients With Recurrent or Progressed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Laura And Isaac Perlmutter Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
A Phase Ib/II Clinical Study of BBI608 in Combination With Temozolomide for Adult Patients With Recurrent or Progressed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
University of Calgary
mi
from
Calgary,
A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
A Phase Ib/II Clinical Study of BBI608 in Combination With Temozolomide for Adult Patients With Recurrent or Progressed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
University of Calgary
mi
from
Calgary,
Click here to add this to my saved trials
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
University of California Irvine, Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
University of California Irvine, Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Emory University
mi
from
Atlanta, GA
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
University of Rochester
mi
from
Rochester, NY
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
UF Health Cancer Center at Orlando Health
mi
from
Orlando, FL
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
UF Health Cancer Center at Orlando Health
mi
from
Orlando, FL
Click here to add this to my saved trials
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin
mi
from
Milwaukee, WI
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Miami Cancer Institute at Baptist Health, Inc.
mi
from
Miami, FL
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Miami Cancer Institute at Baptist Health, Inc.
mi
from
Miami, FL
Click here to add this to my saved trials
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
The University of California, San Diego
mi
from
La Jolla, CA
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
Impact of Cognitive Rehab and Physical Activity on Cognition in Patients With Metastatic Brain Tumors Undergoing RT
Does Cognitive Rehabilitation and Physical Activity Impact Executive Functioning Following Radiation Therapy for Cerebral Metastases? A Pilot Study
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Impact of Cognitive Rehab and Physical Activity on Cognition in Patients With Metastatic Brain Tumors Undergoing RT
Does Cognitive Rehabilitation and Physical Activity Impact Executive Functioning Following Radiation Therapy for Cerebral Metastases? A Pilot Study
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Study of Health Effects of Cosmetic Breast Augmentation
Extended Mortality Follow-Up of Women With Augmentation Mammoplasty
Status: Enrolling
Updated:  12/31/1969
National Cancer Institute , 9000 Rockville Pike
mi
from
Bethesda, MD
Study of Health Effects of Cosmetic Breast Augmentation
Extended Mortality Follow-Up of Women With Augmentation Mammoplasty
Status: Enrolling
Updated: 12/31/1969
National Cancer Institute , 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Anchorage Associates in Radiation Medicine
mi
from
Anchorage, AK
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Anchorage Associates in Radiation Medicine
mi
from
Anchorage, AK
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Anchorage Radiation Therapy Center
mi
from
Anchorage, AK
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Anchorage Radiation Therapy Center
mi
from
Anchorage, AK
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Alaska Breast Care and Surgery LLC
mi
from
Anchorage, AK
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Alaska Breast Care and Surgery LLC
mi
from
Anchorage, AK
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Alaska Oncology and Hematology LLC
mi
from
Anchorage, AK
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Alaska Oncology and Hematology LLC
mi
from
Anchorage, AK
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Alaska Women's Cancer Care
mi
from
Anchorage, AK
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Alaska Women's Cancer Care
mi
from
Anchorage, AK
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Anchorage Oncology Centre
mi
from
Anchorage, AK
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Anchorage Oncology Centre
mi
from
Anchorage, AK
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Katmai Oncology Group
mi
from
Anchorage, AK
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Katmai Oncology Group
mi
from
Anchorage, AK
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Providence Alaska Medical Center
mi
from
Anchorage, AK
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Providence Alaska Medical Center
mi
from
Anchorage, AK
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Providence Saint Joseph Medical Center-Disney Family Cancer Center
mi
from
Burbank, CA
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Providence Saint Joseph Medical Center-Disney Family Cancer Center
mi
from
Burbank, CA
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Beebe Medical Center
mi
from
Lewes, DE
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Beebe Medical Center
mi
from
Lewes, DE
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Delaware Clinical & Laboratory Physicians, PA
mi
from
Newark, DE
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Delaware Clinical & Laboratory Physicians, PA
mi
from
Newark, DE
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Helen F. Graham Cancer Center
mi
from
Newark, DE
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Helen F. Graham Cancer Center
mi
from
Newark, DE
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Medical Oncology Hematology Consultants
mi
from
Newark, DE
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Medical Oncology Hematology Consultants
mi
from
Newark, DE
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Regional Hematology and Oncology PA
mi
from
Newark, DE
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Regional Hematology and Oncology PA
mi
from
Newark, DE
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Christiana Care Health System - Christiana Hospital
mi
from
Newark, DE
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Christiana Care Health System - Christiana Hospital
mi
from
Newark, DE
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Beebe Health Campus
mi
from
Rehoboth Beach, DE
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Beebe Health Campus
mi
from
Rehoboth Beach, DE
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Nanticoke Memorial Hospital
mi
from
Seaford, DE
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Nanticoke Memorial Hospital
mi
from
Seaford, DE
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Christiana Care Health System-Wilmington Hospital
mi
from
Wilmington, DE
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Christiana Care Health System-Wilmington Hospital
mi
from
Wilmington, DE
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Summit Cancer Care-Memorial
mi
from
Savannah, GA
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Summit Cancer Care-Memorial
mi
from
Savannah, GA
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Low Country Cancer Care Associates PC
mi
from
Savannah, GA
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Low Country Cancer Care Associates PC
mi
from
Savannah, GA
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Saint Alphonsus Cancer Care Center-Boise
mi
from
Boise, ID
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Saint Alphonsus Cancer Care Center-Boise
mi
from
Boise, ID
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Mountain States Tumor Institute
mi
from
Boise, ID
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Mountain States Tumor Institute
mi
from
Boise, ID
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Saint Alphonsus Cancer Care Center-Caldwell
mi
from
Caldwell, ID
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Saint Alphonsus Cancer Care Center-Caldwell
mi
from
Caldwell, ID
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Kootenai Medical Center
mi
from
Coeur d'Alene, ID
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Kootenai Medical Center
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Walter Knox Memorial Hospital
mi
from
Emmett, ID
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Walter Knox Memorial Hospital
mi
from
Emmett, ID
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Mountain States Tumor Institute - Fruitland
mi
from
Fruitland, ID
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Mountain States Tumor Institute - Fruitland
mi
from
Fruitland, ID
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Idaho Urologic Institute - Meridian
mi
from
Meridian, ID
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Idaho Urologic Institute - Meridian
mi
from
Meridian, ID
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Mountain States Tumor Institute - Meridian
mi
from
Meridian, ID
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Mountain States Tumor Institute - Meridian
mi
from
Meridian, ID
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Saint Alphonsus Medical Center-Nampa
mi
from
Nampa, ID
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Saint Alphonsus Medical Center-Nampa
mi
from
Nampa, ID
Click here to add this to my saved trials
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Mountain States Tumor Institute - Nampa
mi
from
Nampa, ID
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Mountain States Tumor Institute - Nampa
mi
from
Nampa, ID
Click here to add this to my saved trials